| Literature DB >> 33598013 |
Damian R Maciejewski1, Łukasz Tekieli1, Mariusz Trystuła2, Tomasz Tomaszewski3, Roman Machnik2, Jacek Legutko1, Marek Kazibudzki2, Robert Musiał4, Marcin Misztal2,5, Piotr Pieniążek1,2,6.
Abstract
INTRODUCTION: Radial or brachial access may be preferred in the case of severe peripheral artery disease (PAD) or difficult aortic arch anatomy during carotid artery stenting (CAS). AIM: To evaluate the clinical conditions indicating potential benefit from non-femoral access as well as feasibility and safety of transradial/transbrachial access (TRA/TBA) as an alternative approach for CAS.Entities:
Keywords: brachial approach; carotid artery stenting; peripheral artery disease; radial approach
Year: 2020 PMID: 33598013 PMCID: PMC7863832 DOI: 10.5114/aic.2020.101765
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Figure 1A – Left internal carotid artery stenosis (large arrow). TBC – truncus brachiocephalicus and bovine arch (thin arrow). B – Selective angiography confirming critical stenosis of the left internal carotid artery. C – Self-expanding Carotid Wallstent (Boston Scientific) 7 mm × 30 mm delivery (white arrow). D – Ultra Soft (Boston Scientific) 5.0 mm × 20 mm balloon post-dilatation. E – Final angiography of carotid stenting
Figure 2A – Excessive protrusion of subclavian stent into the aortic arch (black arrow). B – Successful cannulation of the right common carotid artery with 7 Fr Guider Softip (Boston Scientific) guiding catheter via the right radial artery. C – Selective angiography confirming critical stenosis of the right internal carotid artery. D – Self-expanding Precise (Cordis) 8 mm × 30 mm post-dilatation with 5.0 mm × 20 mm balloon. E – Final angiography showing optimal effect of RICA-CAS
Patient baseline characteristics and indications for radial/brachial access (n = 67). Propensity score matching between TRA/TBA and TFA CAS at 1 : 1 ratio
| Parameter | Value | ||||
|---|---|---|---|---|---|
| Demography and comorbidities: | |||||
| Age [years] | 70 ±8.6 | ||||
| Gender, men | 44 (65.7) | ||||
| Stroke/TIA | 28 (41.8) | ||||
| Hypertension | 66 (98.5) | ||||
| Diabetes mellitus | 21 (31.3) | ||||
| Dyslipidaemia | 66 (98.5) | ||||
| Coronary artery disease | 43 (64.2) | ||||
| Previous percutaneous intervention coronary | 24 (35.8) | ||||
| Previous myocardial infarction | 16 (23.9) | ||||
| History of coronary artery bypass grafting | 9 (13.4) | ||||
| Indication for radial/brachial access: | |||||
| Severe peripheral artery disease | 35 (52.2) | ||||
| Bovine arch | 10 (14.9) | ||||
| Obesity, BMI > 35 kg/m2 | 9 (13.4) | ||||
| Severe degenerative disease of the spine | 7 (10.5) | ||||
| Type III aortic arch | 5 (7.5) | ||||
| Excessive protrusion of the subclavian stent into the aortic arch | 1 (1.5) | ||||
| Propensity score matching | |||||
| Parameter | TRA/TBA ( | TFA ( | |||
| Age [years] | 69.8 ±8.7 | 69.2 ±8.6 | 0.687 | ||
| Gender, men | 41 (65.1) | 43 (68.3) | 0.705 | ||
| Stroke/TIA | 26 (41.3) | 25 (39.7) | 0.856 | ||
| Diabetes mellitus | 19 (30.2) | 23 (36.5) | 0.450 | ||
| Previous percutaneous intervention coronary | 23 (36.5) | 25 (39.7) | 0.714 | ||
| Previous myocardial infarction | 15 (23.8) | 15 (23.8) | 1.000 | ||
| History of coronary artery bypass grafting | 9 (14.3) | 8 (12.7) | 0.794 | ||
| Contralateral carotid occlusion | 11 (17.5) | 10 (15.9) | 0.811 | ||
| Percentage of carotid artery stenosis | 81.5 ±8.2 | 81.7 ±8.1 | 0.744 | ||
Values are mean ± SD or n (%).
Procedural data (n = 67)
| Parameter | Value | |
|---|---|---|
| Right carotid artery | 39 (58.2%) | |
| Left carotid artery | 28 (41.8%) | |
| Contralateral occlusion | 11 (16.4%) | |
| Technical success rate by radial/brachial access: | 63 | |
| Transradial access | 59 | |
| Transbrachial access | 4 | |
| Direct stenting | 30 (47.6%) | |
| Angiographic stenosis evaluation (%): | ||
| Pre-intervention | 81.5 ±8.2 | |
| Post-intervention | 9.1 ±7.6 | |
| Stent type: | ||
| Carotid Wallstent (Boston Scientific) | 33 (52.3%) | |
| Roadsaver (Terumo) | 18 (28.6%) | |
| Cristallo Idealle (Medtronic) | 6 (9.5%) | |
| Precise (Cordis) | 3 (4.8%) | |
| Mer (Balton) | 3 (4.8%) | |
| Neuroprotection type: | ||
| Spider FX (Medtronic) | 29 (46%) | |
| FilterWire EZ (Boston Scientific) | 19 (30.2%) | |
| Wirion (Allium Medical) | 9 (14.3%) | |
| Emboshield (Abbott) | 6 (9.5%) | |